Erratum: Design of Selective, ATP-Competitive Inhibitors of Akt [Journal of Medicinal Chemistry (2010) 53 (4615) DOI: 10.1021/jm1003842;Design of selective, ATP-competitive inhibitors of akt

Journal of Medicinal Chemistry

Volumn 53, Issue 12, 2010, Pages 4615-4622

  Freeman Cook, Kevin D ^a   Autry, Christopher ^a   Borzillo, Gary ^a   Gordon, Deborah ^a   Barbacci Tobin, Elsa ^a   Bernardo, Vincent ^a   Briere, David ^a   Clark, Tracey ^a   Corbett, Matthew ^a   Jakubczak, John ^a   Kakar, Shefali ^a   Knauth, Elizabeth ^a   Lippa, Blaise ^a   Luzzio, Michael J ^a   Mansour, Mahmoud ^a   Martinelli, Gary ^a   Marx, Matthew ^a   Nelson, Kendra ^a   Pandit, Jayvardhan ^a   Rajamohan, Francis ^a   Robinson, Shaughnessy ^a   Subramanyam, Chakrapani ^a   Wei, Liuqing ^a   Wythes, Martin ^a   Morris, Joel ^a   more..

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 METHYL 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL) 3((PHENYLAMINO)METHYL)PYRROLIDIN 3 AMINE; N ((3 AMINO 1 (5 ETHYL 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL) PYRROLIDIN 3 YL)METHYL) 2,4 DIFLUOROBENZAMIDE; N ((3 AMINO 1 (5 METHYL 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL) PYRROLIDIN 3 YL)METHYL) 4 FLUOROBENZAMIDE; N ((3 AMINO 1 (5 METHYL 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL) PYRROLIDIN 3 YL)METHYL)BENZAMIDE; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLORECTAL CARCINOMA; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; LIPOPHILICITY; MOUSE; NONHUMAN; PROSTATE CARCINOMA; STRUCTURE ACTIVITY RELATION;

EID: 77953758752     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100769x     Document Type: Erratum

References (53)

1. Bellacosa, A.; Testa, J. R.; Staal, S. P.; Tsichlis, P. N. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region Science 1991, 254, 274-277
2. Altomare, D. A.; Testa, J. R. Perturbations of the AKT signaling pathway in human cancer Oncogene 2005, 24, 7455-7464
3. Dudek, H.; Datta, S. R.; Franke, T. F.; Birnbaum, M. J.; Yao, R.; Cooper, G. M.; Segal, R. A.; Kaplan, D. R.; Greenberg, M. E. Regulation of neuronal survival by the serine-threonine protein kinase Akt Science 1997, 275, 661-665
4. Nicholson, K. M.; Anderson, N. G. The protein kinase B/Akt signalling pathway in human malignancy Cell. Signalling 2002, 14, 381-395
5. Cheng, J. Q.; Lindsley, C. W.; Cheng, G. Z.; Yang, H.; Nicosia, S. V. The Akt/PKB pathway: molecular target for cancer drug discovery Oncogene 2005, 24, 7482-7492
6. Vlietstra, R. J.; Van Alewijk, D. C. J. G.; Hermans, K. G. L.; Van Steenbrugge, G. J.; Trapman, J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts Cancer Res. 1998, 58, 2720-2723
7. Yuan, Z. Q.; Sun, M.; Feldman, R. I.; Wang, G.; Ma, X.-L.; Jiang, C.; Coppola, D.; Nicosia, S. V.; Cheng, J. Q. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer Oncogene 2000, 19, 2324-2330
8. Tokunaga, E.; Kimura, Y.; Oki, E.; Ueda, N.; Futatsugi, M.; Mashino, K.; Yamamoto, M.; Ikebe, M.; Kakeji, Y.; Baba, H.; Maehara, Y. Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients Int. J. Cancer 2005, 118, 284-289
9. Tokunaga, E.; Kataoka, A.; Kimura, Y.; Oki, E.; Mashino, K.; Nishida, K.; Koga, T.; Morita, M.; Kakeji, Y.; Baba, H.; Ohno, S.; Maehara, Y. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer Eur. J. Cancer 2006, 42, 629-635
10. Hennessy, B. T.; Smith, D. L.; Ram, P. T.; Lu, Y.; Mills, G. B. Exploiting the PI3K/AKT pathway for cancer drug discovery Nat. Rev. Drug Discovery 2005, 4, 988-1004
11. Yap, T. A.; Garrett, M. D.; Walton, M. I.; Raynaud, F.; de Bono, J. S.; Workman, P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises Curr. Opin. Pharmacol. 2008, 8, 393-412
12. Garcia-Echeverria, C.; Sellers, W. R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer Oncogene 2008, 27, 5511-5526
13. Lindsley, C. W.; Barnett, S. F.; Layton, M. E.; Bilodeau, M. T. The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors Curr. Cancer Drug Targets 2008, 8, 7-18
14. Cheng, G. Z.; Park, S.; Shu, S.; He, L.; Kong, W.; Zhang, W.; Yuan, Z.; Wang, L.-H.; Cheng, J. Q. Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery Curr. Cancer Drug Targets 2008, 8, 2-6
15. Meric-Bernstam, F.; Gonzalez-Angulo, A. M. Targeting the mTOR signaling network for cancer therapy J. Clin. Oncol. 2009, 27, 2278-2287
16. Ayral-Kaloustian, S.; Gu, J.; Lucas, J.; Cinque, M.; Gaydos, C.; Zask, A.; Chaudhary, I.; Wang, J.; Di, L.; Young, M.; Ruppen, M.; Mansour, T. S.; Gibbons, J. J.; Yu, K. Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates J. Med. Chem. 2010, 53, 452-459
17. Sun, C. L.; Li, X. Rapamycin Analogs as Anti-Cancer Agents. WO/2009/131631, 2009.
18. Chresta, C. M.; Davies, B. R.; Hickson, I.; Harding, T.; Cosulich, S.; Critchlow, S. E.; Vincent, J. P.; Ellston, R.; Jones, D.; Sini, P.; James, D.; Howard, Z.; Dudley, P.; Hughes, G.; Smith, L.; Maguire, S.; Hummersone, M.; Malagu, K.; Menear, K.; Jenkins, R.; Jacobsen, M.; Smith, G. C. M.; Guichard, S.; Pass, M. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity Cancer Res. 2010, 70, 288-298
19. Marone, R.; Cmiljanovic, V.; Giese, B.; Wymann, M. P. Targeting phosphoinositide 3-kinase-moving towards therapy Biochim. Biophys. Acta, Proteins Proteomics 2008, 1784, 159-185
20. Folkes, A. J.; Ahmadi, K.; Alderton, W. K.; Alix, S.; Baker, S. J.; Box, G.; Chuckowree, I. S.; Clarke, P. A.; Depledge, P.; Eccles, S. A.; Friedman, L. S.; Hayes, A.; Hancox, T. C.; Kugendradas, A.; Lensun, L.; Moore, P.; Olivero, A. G.; Pang, J.; Patel, S.; Pergl-Wilson, G. H.; Raynaud, F. I.; Robson, A.; Saghir, N.; Salphati, L.; Sohal, S.; Ultsch, M. H.; Valenti, M.; Wallweber, H. J. A.; Wan, N. C.; Wiesmann, C.; Workman, P.; Zhyvoloup, A.; Zvelebil, M. J.; Shuttleworth, S. J. The identification of 2-(1 H -indazol-4-yl)-6-(4- methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2- d ]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer J. Med. Chem. 2008, 51, 5522-5532
21. Lohar, M. V.; Mundada, R.; Bhonde, M.; Padgaonkar, A.; Deore, V.; Yewalkar, N.; Bhatia, D.; Rathos, M.; Joshi, K.; Vishwakarma, R. A.; Kumar, S. Design and synthesis of novel furoquinoline based inhibitors of multiple targets in the PI3K/Akt-mTOR pathway Bioorg. Med. Chem. Lett. 2008, 18, 3603-3606
22. Fan, Q.-W.; Knight, Z. A.; Goldenberg, D. D.; Yu, W.; Mostov, K. E.; Stokoe, D.; Shokat, K. M.; Weiss, W. A. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma Cancer Cell 2006, 9, 341-349
23. Maira, S.-M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; Brachmann, S.; Chene, P.; De Pover, A.; Schoemaker, K.; Fabbro, D.; Gabriel, D.; Simonen, M.; Murphy, L.; Finan, P.; Sellers, W.; Garcia-Echeverria, C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity Mol. Cancer Ther. 2008, 7, 1851-1863
24. Saxty, G.; Woodhead, S. J.; Berdini, V.; Davies, T. G.; Verdonk, M. L.; Wyatt, P. G.; Boyle, R. G.; Barford, D.; Downham, R.; Garrett, M. D.; Carr, R. A. Identification of inhibitors of protein kinase B using fragment-based lead discovery J. Med. Chem. 2007, 50, 2293-2296
25. Lin, X.; Murray, J. M.; Rico, A. C.; Wang, M. X.; Chu, D. T.; Zhou, Y.; Del Rosario, M.; Kaufman, S.; Ma, S.; Fang, E.; Crawford, K.; Jefferson, A. B. Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies Bioorg. Med. Chem. Lett. 2006, 16, 4163-4168
26. Woods, K. W.; Fischer, J. P.; Claiborne, A.; Li, T.; Thomas, S. A.; Zhu, G.-D.; Diebold, R. B.; Liu, X.; Shi, Y.; Klinghofer, V.; Han, E. K.; Guan, R.; Magnone, S. R.; Johnson, E. F.; Bouska, J. J.; Olson, A. M.; de Jong, R.; Oltersdorf, T.; Luo, Y.; Rosenberg, S. H.; Giranda, V. L.; Li, Q. Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors Bioorg. Med. Chem. 2006, 14, 6832-6846
27. Donald, A.; McHardy, T.; Rowlands, M. G.; Hunter, L.-J. K.; Davies, T. G.; Berdini, V.; Boyle, R. G.; Aherne, G. W.; Garrett, M. D.; Collins, I. Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design J. Med. Chem. 2007, 50, 2289-2292
28. Zhu, G.-D.; Gong, J.; Gandhi, V. B.; Woods, K.; Luo, Y.; Liu, X.; Guan, R.; Klinghofer, V.; Johnson, E. F.; Stoll, V. S.; Mamo, M.; Li, Q.; Rosenberg, S. H.; Giranda, V. L. Design and synthesis of pyridine-pyrazolopyridine-based inhibitors of protein kinase B/Akt Bioorg. Med. Chem. 2007, 15, 2441-2452
29. Zhu, G.-D.; Gandhi, V. B.; Gong, J.; Thomas, S.; Woods, K. W.; Song, X.; Li, T.; Diebold, R. B.; Luo, Y.; Liu, X.; Guan, R.; Klinghofer, V.; Johnson, E. F.; Bouska, J.; Olson, A.; Marsh, K. C.; Stoll, V. S.; Mamo, M.; Polakowski, J.; Campbell, T. J.; Martin, R. L.; Gintant, G. A.; Penning, T. D.; Li, Q.; Rosenberg, S. H.; Giranda, V. L. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension J. Med. Chem. 2007, 50, 2990-3003
30. Caldwell, J. J.; Davies, T. G.; Donald, A.; McHardy, T.; Rowlands, M. G.; Aherne, G. W.; Hunter, L. K.; Taylor, K.; Ruddle, R.; Raynaud, F. I.; Verdonk, M.; Workman, P.; Garrett, M. D.; Collins, I. Identification of 4-(4-aminopiperidin-1-yl)-7 H -pyrrolo[2,3- d ]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration J. Med. Chem. 2008, 51, 2147-2157
31. Zhao, Z.; Robinson, R. G.; Barnett, S. F.; Defeo-Jones, D.; Jones, R. E.; Hartman, G. D.; Huber, H. E.; Duggan, M. E.; Lindsley, C. W. Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity Bioorg. Med. Chem. Lett. 2008, 18, 49-53
32. Lindsley, C. W.; Zhao, Z.; Leister, W. H.; Robinson, R. G.; Barnett, S. F.; Defeo-Jones, D.; Jones, R. E.; Hartman, G. D.; Huff, J. R.; Huber, H. E.; Duggan, M. E. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors Bioorg. Med. Chem. Lett. 2005, 15, 761-764
33. Zhao, Z.; Leister, W. H.; Robinson, R. G.; Barnett, S. F.; Defeo-Jones, D.; Jones, R. E.; Hartman, G. D.; Huff, J. R.; Huber, H. E.; Duggan, M. E.; Lindsley, C. W. Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors Bioorg. Med. Chem. Lett. 2005, 15, 905-909
34. Siu, T.; Li, Y.; Nagasawa, J.; Liang, J.; Tehrani, L.; Chua, P.; Jones, R. E.; Defeo-Jones, D.; Barnett, S. F.; Robinson, R. G. The design and synthesis of potent and cell-active allosteric dual Akt 1 and 2 inhibitors devoid of hERG activity Bioorg. Med. Chem. Lett. 2008, 18, 4191-4194
35. Siu, T.; Liang, J.; Arruda, J.; Li, Y.; Jones, R. E.; Defeo-Jones, D.; Barnett, S. F.; Robinson, R. G. Discovery of potent and cell-active allosteric dual Akt 1 and 2 inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 4186-4190
36. Wu, Z.; Robinson, R. G.; Fu, S.; Barnett, S. F.; Defeo-Jones, D.; Jones, R. E.; Kral, A. M.; Huber, H. E.; Kohl, N. E.; Hartman, G. D.; Bilodeau, M. T. Rapid assembly of diverse and potent allosteric Akt inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 2211-2214
37. Bilodeau, M. T.; Balitza, A. E.; Hoffman, J. M.; Manley, P. J.; Barnett, S. F.; Defeo-Jones, D.; Haskell, K.; Jones, R. E.; Leander, K.; Robinson, R. G.; Smith, A. M.; Huber, H. E.; Hartman, G. D. Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model Bioorg. Med. Chem. Lett. 2008, 18, 3178-3182
38. Li, Y.; Liang, J.; Siu, T.; Hu, E.; Rossi, M. A.; Barnett, S. F.; Defeo-Jones, D.; Jones, R. E.; Robinson, R. G.; Leander, K.; Huber, H. E.; Mittal, S.; Cosford, N.; Prasit, P. Allosteric inhibitors of Akt1 and Akt2: discovery of [1,2,4]triazolo[3,4- f ][1,6]naphthyridines with potent and balanced activity Bioorg. Med. Chem. Lett. 2009, 19, 834-836
39. Lippa, B.; Pan, G.; Corbett, M.; Li, C.; Kauffman, G. S.; Pandit, J.; Robinson, S.; Wei, L.; Kozina, E.; Marr, E. S.; Borzillo, G.; Knauth, E.; Barbacci-Tobin, E. G.; Vincent, P.; Troutman, M.; Baker, D.; Rajamohan, F.; Kakar, S.; Clark, T.; Morris, J. Synthesis and structure based optimization of novel Akt inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 3359-3363
40. Heerding, D. A.; Rhodes, N.; Leber, J. D.; Clark, T. J.; Keenan, R. M.; Lafrance, L. V.; Li, M.; Safonov, I. G.; Takata, D. T.; Venslavsky, J. W.; Yamashita, D. S.; Choudhry, A. E.; Copeland, R. A.; Lai, Z.; Schaber, M. D.; Tummino, P. J.; Strum, S. L.; Wood, E. R.; Duckett, D. R.; Eberwein, D.; Knick, V. B.; Lansing, T. J.; McConnell, R. T.; Zhang, S. Y.; Minthorn, E. A.; Concha, N. O.; Warren, G. L.; Kumar, R. Identification of 4-(2-(4-amino-1,2,5-oxadiazol- 3-yl)-1-ethyl-7-{[(3 S)-3-piperidinylmethyl]oxy}-1 H -imidazo[4,5- c ]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase J. Med. Chem. 2008, 51, 5663-5679
41. Unpublished results.
42. Tomita, K.; Tsuzuki, Y.; Shibamori, K.-i.; Tashima, M.; Kajikawa, F.; Sato, Y.; Kashimoto, S.; Chiba, K.; Hino, K. Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8- naphthyridine-3-carboxylic acids as antitumor agents. Part 1 J. Med. Chem. 2002, 45, 5564-5575
43. Much of the SAR was developed in the racemic series, with periodic checks to confirm that the trend of improved potency and selectivity was consistently achieved with a single enantiomer. This was true in all cases examined, and the absolute stereochemistry was determined for advanced analogues (cf. Table 6).
44. Obach, R. S. The prediction of human clearance from hepatic microsomal metabolism data Curr. Opin. Drug Discovery Dev. 2001, 4, 36-44
45. 3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: comparison of intact cell and membrane preparations and effects of altering [K+]o J. Pharmacol. Toxicol. Methods 2004, 50, 187-199
46. Finlayson, K.; Sharkey, J. A High-Throughput Binding Assay for HERG. In Optimization in Drug Discovery: In Vitro Methods; Yan, Z.; Caldwell, G. W., Eds.; Methods in Pharmacology and Toxicology; Springer: Secaucus, NJ; 2004; pp 353 - 368
47. 3H]Dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen Eur. J. Pharmacol. 2001, 430, 147-148
48. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890
49. Ryckmans, T.; Edwards, M. P.; Horne, V. A.; Correia, A. M.; Owen, D. R.; Thompson, L. R.; Tran, I.; Tutt, M. F.; Young, T. Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: a lipophilic efficiency (LipE) analysis Bioorg. Med. Chem. Lett. 2009, 19, 4406-4409
50. Mai, K.; Patil, G. Asymmetric synthesis of α-aminonitriles Synth. Commun. 1984, 14, 1299-1304
51. Corbett, M. S.; Kauffman, G. S.; Freeman-Cook, K. D.; Lippa, B. S.; Luzzio, M. J.; Morris, J. Amine Derivatives Useful as Anticancer Agents and Their Preparation, Pharmaceutical Compositions and Use in the Treatment of Neoplasm. 2007-IB20652008012635, 20070713, 2008.
52. 50 values of 9 and 12 nM against Akt2 and Akt3, respectively.
53. See Supporting Information sections VI and VII for a full description of rat and dog pharmacokinetic studies, protein binding data, and mouse pharmacodynamic models measuring mouse exposure and phospho-Akt induction in tumors.